No Data
Chengdu Easton Biopharmaceuticals (688513): Developing core areas of precision hemp, promoting synergy among multiple business sectors.
Key points for the first three quarters of 2024, the company's revenue was 1.04 billion, a year-on-year increase of 22.38%; net income attributable to the parent company was 0.217 billion yuan, a year-on-year increase of 12.03%; non-net profit attributable to the parent company was 0.168 billion yuan, year-on-year
Yuandong Biology: Report for the third quarter of 2024
Chengdu Easton Biopharmaceuticals (688513.SH) released its performance for the first three quarters, with a net income of 0.217 billion yuan, a year-on-year increase of 12.03%.
Chengdu Easton Biopharmaceuticals (688513.SH) disclosed its third quarter report for 2024, achieving revenue of 10...
Chengdu Easton Biopharmaceuticals (688513.SH): The net income in the first three quarters was 0.217 billion yuan, an increase of 12.03% year-on-year.
GLEONET reported its third-quarter financial results on October 24. The revenue was 1.04 billion yuan, an increase of 22.38% year-on-year, with a net income of 0.217 billion yuan, a year-on-year increase of 12.03%, non-GAAP net income of 0.168B yuan, a year-on-year increase of 14.92%, and a basic EPS of 1.24 yuan.
chengdu Easton Biopharmaceuticals (688513) company brief review report: domestic preparation new varieties, export preparation continued to increase, performance entered a rapid growth stage.
The impact of centralized procurement is gradually being cleared, and new formulations are expected to continue to contribute to performance growth. We believe that the company's existing key products have been gradually included in centralized procurement, and the negative impact of price reduction on performance has been fully digested. On the basis of price stability and volume growth, existing products generate revenue.
Express News | Chengdu Easton Biopharmaceuticals: The company's products have successfully obtained carbon footprint certification.
No Data
No Data